Mackie reckons it underestimated potential of Theratechnologies’ HIV drug

Mackie reckons it underestimated potential of Theratechnologies' HIV drug

Theratechnologies Inc (TSX:TH) had its ‘buy’ rating repeated by broker Mackie, which also lifts the target price after it reckons it has underestimated the market potential for the firm’s HIV drug ibalizumab. Read More

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s